Walgreens Statement on FDA Emergency Use Authorization of Johnson & Johnson's COVID-19 Vaccine

 The U.S. Food and Drug Administration today approved Johnson & Johnson’s single-dose COVID-19 vaccine for emergency use, marking another historic milestone in helping the nation emerge from the pandemic. Walgreens will continue to work with the Centers for Disease Control and Prevention, the Advisory Committee on Immunization Practices, and federal and state governments to support the administration of Johnson & Johnson’s newly authorized vaccine, once available.
“Walgreens has been at the forefront of administering COVID-19 vaccines since they became available in December,” said John Standley, president, Walgreens. “Our pharmacists and technicians have provided more than 3.5 million COVID-19 vaccinations across our most vulnerable populations, including those in underserved communities. Johnson & Johnson’s single-dose vaccine provides yet another powerful tool to help turn the tide on this pandemic.”
As part of the Federal Retail Pharmacy Program, Walgreens is currently administering a weekly allocation of more than 480,000 COVID-19 vaccine doses from Pfizer and Moderna to eligible individuals across 28 states and jurisdictions, including:
  • Arizona, Alaska, California, Chicago, Connecticut, Delaware, Georgia, Illinois, Kentucky, Maine, Maryland, Nevada, New Hampshire, New Mexico, New York, New York City, North Carolina, Ohio, Oregon, Puerto Rico, South Carolina, U.S. Virgin Islands, Utah, Vermont, Virginia, West Virginia, Wisconsin and Wyoming.
Walgreens is leveraging several different models of care to reach vulnerable and underserved communities across the nation, including in-store and off-site vaccination clinics. While inventory remains limited, eligible individuals can schedule appointments by visiting Walgreens.com/ScheduleVaccine, calling 1-800-Walgreens or through their state department of health website.

Explore Themes in this Press Release